G
SRPT icon

GenTrust’s Sarepta Therapeutics SRPT Stock Holding History

GenTrust’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,461
Closed -$205K – 85
2016
Q4 		$205K Buy
+7,461
New +$300K 0.04% 79

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GenTrust's SRPT Position: Q1 2017 in Review

GenTrust sold out of Sarepta Therapeutics (SRPT) in Q1 2017, closing a stake of 7,461 shares — an estimated $205K sold.

GenTrust first reported a position in SRPT in Q4 2016 and held it in 1 quarter. The position peaked at $205K in Q4 2016. 179 funds tracked by Wall St. Rank hold SRPT as of Q1 2017.

  • GenTrust reported no remaining Sarepta Therapeutics position as of Q1 2017 after selling out during the quarter.
  • GenTrust sold 7,461 Sarepta Therapeutics shares in Q1 2017, an estimated $205K.
  • GenTrust first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 1 quarter.
  • GenTrust's Sarepta Therapeutics position peaked at $205K in Q4 2016.
  • 179 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2017.

Based on GenTrust's 13F filing for Q1 2017, filed 15 May 2017.